MARKET

KPTI

KPTI

Karyopharm Therapeutics Inc
NASDAQ
1.470
-0.040
-2.65%
Closed 18:43 03/18 EDT
OPEN
1.520
PREV CLOSE
1.510
HIGH
1.620
LOW
1.450
VOLUME
1.38M
TURNOVER
0
52 WEEK HIGH
4.870
52 WEEK LOW
0.6174
MARKET CAP
169.15M
P/E (TTM)
-1.1734
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at KPTI last week (0311-0315)?
Weekly Report · 1d ago
Onco360 Selected As The Preferred National Specialty Pharmacy Partner For Karyopharm's Product XPOVIO, A First-In-Class, XPO-1 Inhibitor
Onco360 is now the national specialty pharmacy network partner for Karyopharm's product XPOVIO (selinexor), a first-in-class, XPO-1 inhibitor. The drug is approved in multiple oncology indications for multiple myeloma. Only 50 percent of patients diagnosed with the incurable disease survive past five years.
Benzinga · 5d ago
Weekly Report: what happened at KPTI last week (0304-0308)?
Weekly Report · 03/11 09:06
Big Pharma patent cliffs seen fueling oncology M&A this year
Big Pharma patent cliffs seen fueling oncology M&A this year. Around $182B in revenue is at risk over the next four years due to patent expirations. Cantor Fitzgerald sees between five and 17 acquisition deals for oncologists in 2014. The global market for cancer drugs is expected to grow from $180B in 2022 to $323B in 2028.
Seeking Alpha · 03/10 17:08
Karyopharm Therapeutics Inc: Statement of changes in beneficial ownership of securities
Press release · 03/05 14:06
Analysts Offer Insights on Healthcare Companies: Karyopharm Therapeutics (KPTI) and Siemens Healthineers AG (OtherSEMHF)
2 analysts have maintained Buy ratings on Karyopharm Therapeutics and Siemens Healthineers AG. The analyst consensus on the stock is a Strong Buy with an average price target of $5.80. The company’s shares are currently trading at $1.31.
TipRanks · 03/05 08:20
Weekly Report: what happened at KPTI last week (0226-0301)?
Weekly Report · 03/04 09:06
Barclays Gives a Buy Rating to Karyopharm Therapeutics (KPTI)
Karyopharm Therapeutics has an analyst consensus of Strong Buy, with a price target of $5.25. The company is developing drugs for the treatment of cancer and other major diseases. Peter Lawson has an average return of 12.3% and a 49.59% success rate on recommended stocks.
TipRanks · 03/04 07:55
More
About KPTI
Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. It is developing and commercializing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead asset, XPOVIO (selinexor), is marketed in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies, and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It is evaluating eltanexor, oral SINE compound that, like selinexor, selectively blocks the nuclear export protein XPO1.

Webull offers Karyopharm Therapeutics Inc stock information, including NASDAQ: KPTI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KPTI stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading KPTI stock methods without spending real money on the virtual paper trading platform.